Neo Cura Snares 250 Million Yuan in Series A

Neo Cura announced that it has received 250 million yuan in Series A financing led by Kunlun Capital and co-invested by IDG Capital and the previous round of shareholder Alwin Capital Management.

Founded in 2017, Neo Cura is committed to building a multi-omics big data collection platform and a multi-bioomics database, using AI and bioinformatics core technology for in-depth drug target mining and fully automated drug design for clinical innovative RNA drug development And a new generation of safe and efficient clinical precision diagnosis and treatment, providing patients with one-stop full-cycle services from screening, diagnosis, treatment to efficacy monitoring. The company's R&D pipeline covers many indications such as tumor immunotherapy, vaccines, rare diseases and metabolic-related diseases.

In terms of team, Neo Cura currently has a core R&D team of more than 50 people, including dozens of PhDs/postdoctors from famous universities such as Harvard University, Cornell University, Carnegie Mellon, Peking University, Tsinghua University, and Chinese Academy of Sciences. Team members have held core R&D positions in top international research institutions and companies such as Harvard University Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, Allen Institute, etc., and have been in top international scientific research The journal publishes hundreds of articles; professional fields cover genetic testing, AI algorithms, bioinformatics, tumor immunotherapy and vaccine development, etc.; many members have extensive clinical translation experience and have worked in many well-known pharmaceutical companies. The whole process of drug production, clinical and registration.

Since its inception, Neo Cura has focused on the development and clinical exploration of tumor immunity related technologies. With the development of tumor immunology and molecular biology, immunotherapy that mobilizes or stimulates the body's own immune function to inhibit and kill tumor cells has become a new hot spot in the field of malignant tumor treatment in recent years. Among them, tumor neoantigen vaccines have received widespread attention in the industry due to their extremely high clinical application safety and highly efficient and specific anti-tumor immune response stimulation ability.